Almac Discovery and Elasmogen to Share Anti-ROR-1 VNAR Data at American Association of Cancer Annual Meeting
March 20, 2019
Craigavon, N.I., UK, 20 Mar 2019 – Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Elasmogen a biotech company developing next generation therapeutic biologics, today announced they will present a poster on their VNAR-based protein drug conjugates research targeting ROR1 at the upcoming American Association of Cancer Research (AACR) Meeting in Atlanta, Georgia from 29 March to 3 April 2019.
The poster presentation will highlight some initial work demonstrating the versatility of the VNAR platform and the suitability of ROR-1 as a target for these unique protein drug conjugates.
The presentation will be made by Almac Discovery’s Dr Graham Cotton, Head of Protein Therapeutics:
Title: Novel protein drug conjugates targeting ROR1 through the development and exploitation of a drug discovery platform based on small, engineered VNAR domains
Presenting Author: Dr. Graham Cotton
Session: Antibody-drug Conjugates: New Agents and Technologies
Abstract Number: 2854
Location: Exhibit hall B, poster section 9, poster board number 13 – Georgia World Congress Centre
Date and Time: Sunday 31 March 2019 – 1:00 PM – 5:00 PM
Permanent Abstract Number: 222
Should you wish to meet with a representative during AACR please contact Martin Wiles, VP Business Development & Licensing – [email protected].
A copy of the poster will be made available on the Almac Discovery website immediately after the event.
About Almac Discovery
Almac Discovery is a research driven oncology company dedicated to the discovery and development of novel and innovative approaches to the treatment of cancer. Almac Discovery focuses on the discovery to preclinical stage seeking to licence programmes early with a pharmaceutical partner for further development.
Elasmogen is a private, UK-based biologics-focused biopharmaceutical company. The Company has a late stage pre-clinical product portfolio of assets derived from VNARS being developed for inflammatory, autoimmune and oncology indications. The company is interested in partners who would like access to the platform, existing domains and the half-life product enabler, NDure. Contact [email protected] for further information.